This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Examination of ADMA Serum Level and DDAH II (ADSeS)

This study has been completed.
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf Identifier:
First received: March 13, 2012
Last updated: August 2, 2017
Last verified: August 2017

Examination of ADMA (Asymmetric-Dimethylarginine)-serum level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in patients with severe Sepsis and septic shock as prognostic value.

This study looks into ADMA as a good prognostic factor for sepsis. Further more the dependency of the ADMA level to the DDAH II polymorphisms is reviewed this study.

Septic Shock Sepsis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value

Resource links provided by NLM:

Further study details as provided by Universitätsklinikum Hamburg-Eppendorf:

Primary Outcome Measures:
  • ADMA serum levels [ Time Frame: 7 days ]
    measuring of ADMA serum levels on day 1, 3, 7

Secondary Outcome Measures:
  • 28 day mortality [ Time Frame: 28 day ]
  • hospitalisation (ICU and peripheral) [ Time Frame: 28 days ]
  • severity of illness [ Time Frame: 28 days ]
  • DDAH Ii polymorphism [ Time Frame: 28 days ]

Biospecimen Retention:   Samples With DNA
Whole blood

Enrollment: 120
Actual Study Start Date: February 2012
Study Completion Date: April 2017
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
septical patients
inclusion criteria are severe sepsis and septical shock and must be > 18 y/o

Detailed Description:
Secondary targets are the mortality (28 days ICU), the length of hospitalisation in ICU and peripheral station, the severity of the illness (SAPS II score), the SOFA-score values in the progress and the procalcitonin values in the progress

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients > 18 y/o with sepsis and/or septical shock

Inclusion Criteria:

  • >18 y/o
  • sepsis
  • septical shock

Exclusion Criteria:

  • primary cardiogenic shock
  • pregnancy
  • breastfeeding
  • non compliance
  • moribund status
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01632059

Universitätskrankenhaus Hamburg Eppendorf
Hamburg, Germany, 20246
Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Study Director: Stefan Kluge, Priv.-Doz. Director of critical care center
  More Information

Additional Information:
Responsible Party: Universitätsklinikum Hamburg-Eppendorf Identifier: NCT01632059     History of Changes
Other Study ID Numbers: ADSeS (PV3927)
Study First Received: March 13, 2012
Last Updated: August 2, 2017

Keywords provided by Universitätsklinikum Hamburg-Eppendorf:
length of stay

Additional relevant MeSH terms:
Shock, Septic
Systemic Inflammatory Response Syndrome
Pathologic Processes
Shock processed this record on August 22, 2017